-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 5, 2022, NMPA released the latest drug approval information, and CSPC NBP Pharmaceutical's 3-type generic marketing application for zoledronic acid injection was approved, becoming the sixth domestic enterprise of this product
.
In addition, CSPC Zhongnuo Pharmaceutical (Shijiazhuang)'s 2.
2 new drug listing application for mitoxantrone hydrochloride liposome injection has recently entered administrative approval, and good news is coming soon
.
.
In addition, CSPC Zhongnuo Pharmaceutical (Shijiazhuang)'s 2.
2 new drug listing application for mitoxantrone hydrochloride liposome injection has recently entered administrative approval, and good news is coming soon
.
Figure 1: The latest approved products of CSPC
Source: NMPA official website
Figure 2: Sales of zoledronic acid (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Zoledronic acid can be used to treat hypercalcemia caused by malignancy, and in combination with standard antineoplastic drugs for the treatment of bone lesions in patients with bone metastases from solid tumors and in patients with multiple myeloma
.
According to the data of Minet.
com, in 2018, the sales of zoledronic acid in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals have exceeded 2 billion yuan.
It ranks first in the TOP20 drug varieties for the treatment of bone diseases , and the main dosage form on the market is injections
.
.
According to the data of Minet.
com, in 2018, the sales of zoledronic acid in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals have exceeded 2 billion yuan.
It ranks first in the TOP20 drug varieties for the treatment of bone diseases , and the main dosage form on the market is injections
.
Figure 3: Zoledronic acid has previously reviewed companies
Source: Minet Consistency Evaluation Database
Zoledronic acid injection has been approved by 5 companies earlier, among which Yangzijiang, Kelun, Qilu, and Chia Tai Tianqing have been reviewed, and CSPC, the leading domestic echelon, has also won this large variety
.
In addition, zoledronic acid concentrated solution for injection has also been reviewed by 3 companies.
If this variety becomes the target of the seventh batch of national mining, CSPC is expected to participate in the market competition
.
.
In addition, zoledronic acid concentrated solution for injection has also been reviewed by 3 companies.
If this variety becomes the target of the seventh batch of national mining, CSPC is expected to participate in the market competition
.
At present, the liposome preparations that have been listed in the domestic market include doxorubicin hydrochloride liposome injection, amphotericin B liposome for injection and paclitaxel liposome for injection, and doxorubicin hydrochloride liposome of CSPC In 2020, the total sales of plastid injection in the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities has exceeded 2.
5 billion yuan, and it has become the best-selling liposome preparation in China
.
At the same time, CSPC has continued to develop in the field of liposome research and development in recent years.
In August 2020, the company was the first to apply for the listing of 2.
2 new drugs for mitoxantrone hydrochloride liposome injection, which is used for relapse or relapse after at least first-line standard treatment in the past.
For patients with refractory peripheral T-cell lymphoma, if the new drug is successfully approved, it is expected to become the second blockbuster liposome product under CSPC and the fourth liposome product in China
.
5 billion yuan, and it has become the best-selling liposome preparation in China
.
At the same time, CSPC has continued to develop in the field of liposome research and development in recent years.
In August 2020, the company was the first to apply for the listing of 2.
2 new drugs for mitoxantrone hydrochloride liposome injection, which is used for relapse or relapse after at least first-line standard treatment in the past.
For patients with refractory peripheral T-cell lymphoma, if the new drug is successfully approved, it is expected to become the second blockbuster liposome product under CSPC and the fourth liposome product in China
.
Figure 4: New clinical indications for mitoxantrone hydrochloride liposome injection that have been approved
Source: CDE official website
CSPC has placed high expectations on mitoxantrone hydrochloride liposome injection, and five new indications have been approved for clinical use
.
Phase Ib/II clinical trials of the new drug for acute myeloid leukemia are ongoing, and Phase I trials for relapsed/refractory multiple myeloma are also ongoing
.
It is foreseeable that the future market space will be huge with the approval of new indications after the product enters the market
.
.
Phase Ib/II clinical trials of the new drug for acute myeloid leukemia are ongoing, and Phase I trials for relapsed/refractory multiple myeloma are also ongoing
.
It is foreseeable that the future market space will be huge with the approval of new indications after the product enters the market
.
Source: NMPA official website, CDE official website, Minet database
The review data statistics are as of January 6.
If there are any mistakes or omissions, please correct me
.
If there are any mistakes or omissions, please correct me
.
On January 5, 2022, NMPA released the latest drug approval information, and CSPC NBP Pharmaceutical's 3-type generic marketing application for zoledronic acid injection was approved, becoming the sixth domestic enterprise of this product
.
In addition, CSPC Zhongnuo Pharmaceutical (Shijiazhuang)'s 2.
2 new drug listing application for mitoxantrone hydrochloride liposome injection has recently entered administrative approval, and good news is coming soon
.
.
In addition, CSPC Zhongnuo Pharmaceutical (Shijiazhuang)'s 2.
2 new drug listing application for mitoxantrone hydrochloride liposome injection has recently entered administrative approval, and good news is coming soon
.
Figure 1: The latest approved products of CSPC
Source: NMPA official website
Figure 2: Sales of zoledronic acid (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Zoledronic acid can be used to treat hypercalcemia caused by malignancy, and in combination with standard antineoplastic drugs for the treatment of bone lesions in patients with bone metastases from solid tumors and in patients with multiple myeloma
.
According to the data of Minet.
com, in 2018, the sales of zoledronic acid in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals have exceeded 2 billion yuan.
It ranks first in the TOP20 drug varieties for the treatment of bone diseases , and the main dosage form on the market is injections
.
.
According to the data of Minet.
com, in 2018, the sales of zoledronic acid in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals have exceeded 2 billion yuan.
It ranks first in the TOP20 drug varieties for the treatment of bone diseases , and the main dosage form on the market is injections
.
Figure 3: Zoledronic acid has previously reviewed companies
Source: Minet Consistency Evaluation Database
Zoledronic acid injection has been approved by 5 companies earlier, among which Yangzijiang, Kelun, Qilu, and Chia Tai Tianqing have been reviewed, and CSPC, the leading domestic echelon, has also won this large variety
.
In addition, zoledronic acid concentrated solution for injection has also been reviewed by 3 companies.
If this variety becomes the target of the seventh batch of national mining, CSPC is expected to participate in the market competition
.
.
In addition, zoledronic acid concentrated solution for injection has also been reviewed by 3 companies.
If this variety becomes the target of the seventh batch of national mining, CSPC is expected to participate in the market competition
.
At present, the liposome preparations that have been listed in the domestic market include doxorubicin hydrochloride liposome injection, amphotericin B liposome for injection and paclitaxel liposome for injection, and doxorubicin hydrochloride liposome of CSPC In 2020, the total sales of plastid injection in the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities has exceeded 2.
5 billion yuan, and it has become the best-selling liposome preparation in China
.
At the same time, CSPC has continued to develop in the field of liposome research and development in recent years.
In August 2020, the company was the first to apply for the listing of 2.
2 new drugs for mitoxantrone hydrochloride liposome injection, which is used for relapse or relapse after at least first-line standard treatment in the past.
For patients with refractory peripheral T-cell lymphoma, if the new drug is successfully approved, it is expected to become the second blockbuster liposome product under CSPC and the fourth liposome product in China
.
5 billion yuan, and it has become the best-selling liposome preparation in China
.
At the same time, CSPC has continued to develop in the field of liposome research and development in recent years.
In August 2020, the company was the first to apply for the listing of 2.
2 new drugs for mitoxantrone hydrochloride liposome injection, which is used for relapse or relapse after at least first-line standard treatment in the past.
For patients with refractory peripheral T-cell lymphoma, if the new drug is successfully approved, it is expected to become the second blockbuster liposome product under CSPC and the fourth liposome product in China
.
Figure 4: New clinical indications for mitoxantrone hydrochloride liposome injection that have been approved
Source: CDE official website
CSPC has placed high expectations on mitoxantrone hydrochloride liposome injection, and five new indications have been approved for clinical use
.
Phase Ib/II clinical trials of the new drug for acute myeloid leukemia are ongoing, and Phase I trials for relapsed/refractory multiple myeloma are also ongoing
.
It is foreseeable that the future market space will be huge with the approval of new indications after the product enters the market
.
.
Phase Ib/II clinical trials of the new drug for acute myeloid leukemia are ongoing, and Phase I trials for relapsed/refractory multiple myeloma are also ongoing
.
It is foreseeable that the future market space will be huge with the approval of new indications after the product enters the market
.
Source: NMPA official website, CDE official website, Minet database
The review data statistics are as of January 6.
If there are any mistakes or omissions, please correct me
.
If there are any mistakes or omissions, please correct me
.
On January 5, 2022, NMPA released the latest drug approval information, and CSPC NBP Pharmaceutical's 3-type generic marketing application for zoledronic acid injection was approved, becoming the sixth domestic enterprise of this product
.
In addition, CSPC Zhongnuo Pharmaceutical (Shijiazhuang)'s 2.
2 new drug listing application for mitoxantrone hydrochloride liposome injection has recently entered administrative approval, and good news is coming soon
.
.
In addition, CSPC Zhongnuo Pharmaceutical (Shijiazhuang)'s 2.
2 new drug listing application for mitoxantrone hydrochloride liposome injection has recently entered administrative approval, and good news is coming soon
.
Figure 1: The latest approved products of CSPC
Source: NMPA official website
Figure 2: Sales of zoledronic acid (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Zoledronic acid can be used to treat hypercalcemia caused by malignancy, and in combination with standard antineoplastic drugs for the treatment of bone lesions in patients with bone metastases from solid tumors and in patients with multiple myeloma
.
According to the data of Minet.
com, in 2018, the sales of zoledronic acid in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals have exceeded 2 billion yuan.
It ranks first in the TOP20 drug varieties for the treatment of bone diseases , and the main dosage form on the market is injections
.
hospital hospital disease disease disease_.
According to the data of Minet.
com, in 2018, the sales of zoledronic acid in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals have exceeded 2 billion yuan.
It ranks first in the TOP20 drug varieties for the treatment of bone diseases , and the main dosage form on the market is injections
.
Figure 3: Zoledronic acid has previously reviewed companies
enterprise enterprise Source: Minet Consistency Evaluation Database
Zoledronic acid injection has been approved by 5 companies earlier, among which Yangzijiang, Kelun, Qilu, and Chia Tai Tianqing have been reviewed, and CSPC, the leading domestic echelon, has also won this large variety
.
In addition, zoledronic acid concentrated solution for injection has also been reviewed by 3 companies.
If this variety becomes the target of the seventh batch of national mining, CSPC is expected to participate in the market competition
.
.
In addition, zoledronic acid concentrated solution for injection has also been reviewed by 3 companies.
If this variety becomes the target of the seventh batch of national mining, CSPC is expected to participate in the market competition
.
At present, the liposome preparations that have been listed in the domestic market include doxorubicin hydrochloride liposome injection, amphotericin B liposome for injection and paclitaxel liposome for injection, and doxorubicin hydrochloride liposome of CSPC In 2020, the total sales of plastid injection in the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities has exceeded 2.
5 billion yuan, and it has become the best-selling liposome preparation in China
.
At the same time, CSPC has continued to develop in the field of liposome research and development in recent years.
In August 2020, the company was the first to apply for the listing of 2.
2 new drugs for mitoxantrone hydrochloride liposome injection, which is used for relapse or relapse after at least first-line standard treatment in the past.
For patients with refractory peripheral T-cell lymphoma, if the new drug is successfully approved, it is expected to become the second blockbuster liposome product under CSPC and the fourth liposome product in China
.
Pharmacy Pharmacy Pharmacy Standard Standard Standard5 billion yuan, and it has become the best-selling liposome preparation in China
.
At the same time, CSPC has continued to develop in the field of liposome research and development in recent years.
In August 2020, the company was the first to apply for the listing of 2.
2 new drugs for mitoxantrone hydrochloride liposome injection, which is used for relapse or relapse after at least first-line standard treatment in the past.
For patients with refractory peripheral T-cell lymphoma, if the new drug is successfully approved, it is expected to become the second blockbuster liposome product under CSPC and the fourth liposome product in China
.
Figure 4: New clinical indications for mitoxantrone hydrochloride liposome injection that have been approved
Source: CDE official website
CSPC has placed high expectations on mitoxantrone hydrochloride liposome injection, and five new indications have been approved for clinical use
.
Phase Ib/II clinical trials of the new drug for acute myeloid leukemia are ongoing, and Phase I trials for relapsed/refractory multiple myeloma are also ongoing
.
It is foreseeable that the future market space will be huge with the approval of new indications after the product enters the market
.
.
Phase Ib/II clinical trials of the new drug for acute myeloid leukemia are ongoing, and Phase I trials for relapsed/refractory multiple myeloma are also ongoing
.
It is foreseeable that the future market space will be huge with the approval of new indications after the product enters the market
.
Source: NMPA official website, CDE official website, Minet database
Source: NMPA official website, CDE official website, Minet database The review data statistics are as of January 6.
If there are any mistakes or omissions, please correct me
.
If there are any mistakes or omissions, please correct me
.
